CTLA4 and renal cell carcinoma: Thus, several studies have analyzed the predictive value of NLR in patients with advanced RCC who were given immunotherapy in the form of tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs), such as anti-PD-1, anti-PD-L1, or anti-CTLA-4.